Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioCardia, Inc. is a clinical-stage biotechnology company focused on developing cell-based and cellular-derived therapies for the treatment of cardiovascular and pulmonary diseases with high unmet medical need. The company operates within the biotechnology and regenerative medicine industries, with a primary emphasis on ischemic heart disease and heart failure. BioCardia’s business model centers on advancing proprietary therapeutic platforms through clinical development rather than commercial-stage product sales.
The company’s principal revenue drivers to date consist of collaboration revenue, research-related grants, and limited product and service revenue associated with its delivery and biotherapeutic platforms, as it does not yet have FDA-approved therapeutics. BioCardia is uniquely positioned through its combination of cell therapy development and proprietary catheter-based delivery systems, which are designed to enhance precision and efficacy in cardiovascular treatments. The company was founded in 1999 and has evolved from a cardiovascular device-focused enterprise into a regenerative medicine company emphasizing biologic therapies and minimally invasive delivery technologies.
Business Operations
BioCardia’s operations are organized around two primary business segments: Cell Therapy Development and Biotherapeutic Delivery Systems. The Cell Therapy Development segment includes clinical programs such as CardiAMP® Cell Therapy, which utilizes autologous bone marrow-derived cells for the treatment of ischemic heart failure, and CardiALLO™, an allogeneic cell therapy platform. These programs are in various stages of clinical development and represent the company’s core strategic focus.
The Biotherapeutic Delivery Systems segment includes proprietary catheter-based technologies such as Helix™ Transendocardial Delivery System and Morph™ DNA Steering Catheter, which are designed to deliver biologics directly to targeted cardiac tissue. BioCardia operates primarily in the United States and conducts clinical trials through contracted clinical research organizations and hospital partners. The company does not report significant manufacturing operations and relies on third-party vendors for clinical-grade materials and trial support. Public disclosures do not indicate material joint ventures; data on additional subsidiaries is inconclusive based on available public sources.
Strategic Position & Investments
BioCardia’s strategic direction is centered on advancing late-stage clinical trials for its lead programs, particularly CardiAMP® Cell Therapy, with the goal of achieving regulatory approval in the United States. Growth initiatives emphasize clinical validation, regulatory engagement with the U.S. Food and Drug Administration, and potential future commercialization partnerships rather than near-term independent commercialization.
The company has made targeted investments in expanding its intellectual property portfolio related to cell processing and delivery technologies. BioCardia has historically grown through internal development rather than large-scale acquisitions, and no major acquisitions have been consistently reported across public filings and investor disclosures. The company is actively involved in the emerging field of regenerative cardiovascular medicine, leveraging advances in cell biology and interventional cardiology. Information regarding material portfolio investments outside its core programs is inconclusive based on available public sources.
Geographic Footprint
BioCardia is headquartered in San Carlos, California, within the United States, and its primary operational and administrative activities are U.S.-based. The company’s clinical trials are largely conducted at medical centers across North America, reflecting its regulatory focus on the U.S. market.
While BioCardia does not maintain significant physical operations outside the United States, its technologies and intellectual property have international relevance, and certain clinical or research collaborations may involve non-U.S. investigators. The company does not currently report material revenue or operational infrastructure across Europe, Asia-Pacific, or other regions, and its international footprint remains limited and development-oriented.
Leadership & Governance
BioCardia is led by an executive team with experience in biotechnology, medical devices, and cardiovascular therapeutics. The leadership emphasizes disciplined clinical development, regulatory rigor, and the integration of biologic therapies with delivery technologies as a long-term strategic vision.
Key executives include:
- Peter Altman – Chief Executive Officer
- Linda Marbán, Ph.D. – President and Chief Scientific Officer
- Michael D. Bogart – Chief Financial Officer
- Peter E. Altman – Chairman of the Board
The board and executive leadership collectively guide corporate governance, capital allocation, and clinical strategy. While governance practices are described in SEC filings, detailed disclosure on internal leadership philosophy beyond stated strategic priorities is limited in publicly available sources.